vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Metallus Inc. (MTUS). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($308.3M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). Metallus Inc. runs the higher net margin — 1.8% vs -0.7%, a 2.5% gap on every dollar of revenue. On growth, Metallus Inc. posted the faster year-over-year revenue change (9.9% vs 0.7%). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs 2.3%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AVNS vs MTUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $308.3M |
| Net Profit | $-1.3M | $5.4M |
| Gross Margin | 47.5% | 8.1% |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 1.8% |
| Revenue YoY | 0.7% | 9.9% |
| Net Profit YoY | 99.7% | 315.4% |
| EPS (diluted) | $-0.02 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $308.3M | ||
| Q4 25 | $180.9M | $267.3M | ||
| Q3 25 | $177.8M | $305.9M | ||
| Q2 25 | $175.0M | $304.6M | ||
| Q1 25 | $167.5M | $280.5M | ||
| Q4 24 | $179.6M | $240.5M | ||
| Q3 24 | $170.4M | $227.2M | ||
| Q2 24 | $171.7M | $294.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-1.3M | $-14.3M | ||
| Q3 25 | $-1.4M | $8.1M | ||
| Q2 25 | $-76.8M | $3.7M | ||
| Q1 25 | $6.6M | $1.3M | ||
| Q4 24 | $-397.3M | $-21.4M | ||
| Q3 24 | $4.3M | $-5.9M | ||
| Q2 24 | $1.8M | $4.6M |
| Q1 26 | — | 8.1% | ||
| Q4 25 | 47.5% | 2.2% | ||
| Q3 25 | 48.4% | 11.4% | ||
| Q2 25 | 52.6% | 10.6% | ||
| Q1 25 | 53.6% | 7.8% | ||
| Q4 24 | 54.6% | 4.5% | ||
| Q3 24 | 54.5% | 5.3% | ||
| Q2 24 | 55.7% | 8.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | -7.7% | ||
| Q3 25 | 0.1% | 3.6% | ||
| Q2 25 | -42.6% | 2.8% | ||
| Q1 25 | 6.1% | 1.0% | ||
| Q4 24 | -233.0% | -10.1% | ||
| Q3 24 | 7.0% | -3.1% | ||
| Q2 24 | 3.7% | 2.1% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | -0.7% | -5.3% | ||
| Q3 25 | -0.8% | 2.6% | ||
| Q2 25 | -43.9% | 1.2% | ||
| Q1 25 | 3.9% | 0.5% | ||
| Q4 24 | -221.2% | -8.9% | ||
| Q3 24 | 2.5% | -2.6% | ||
| Q2 24 | 1.0% | 1.6% |
| Q1 26 | — | $0.13 | ||
| Q4 25 | $-0.02 | $-0.34 | ||
| Q3 25 | $-0.03 | $0.19 | ||
| Q2 25 | $-1.66 | $0.09 | ||
| Q1 25 | $0.14 | $0.03 | ||
| Q4 24 | $-8.64 | $-0.46 | ||
| Q3 24 | $0.09 | $-0.13 | ||
| Q2 24 | $0.04 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $104.0M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $683.0M |
| Total Assets | $1.1B | $1.1B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $89.8M | $156.7M | ||
| Q3 25 | $70.5M | $191.5M | ||
| Q2 25 | $90.3M | $190.8M | ||
| Q1 25 | $97.0M | $180.3M | ||
| Q4 24 | $107.7M | $240.7M | ||
| Q3 24 | $89.0M | $254.6M | ||
| Q2 24 | $92.2M | $272.8M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | $0 | ||
| Q2 25 | $95.7M | $0 | ||
| Q1 25 | $98.0M | $5.4M | ||
| Q4 24 | $125.3M | $5.4M | ||
| Q3 24 | $152.6M | $13.2M | ||
| Q2 24 | $164.9M | $13.2M |
| Q1 26 | — | $683.0M | ||
| Q4 25 | $778.2M | $686.0M | ||
| Q3 25 | $778.0M | $697.7M | ||
| Q2 25 | $776.3M | $690.0M | ||
| Q1 25 | $839.4M | $686.1M | ||
| Q4 24 | $828.5M | $690.5M | ||
| Q3 24 | $1.2B | $712.7M | ||
| Q2 24 | $1.2B | $736.3M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.0B | $1.1B | ||
| Q1 25 | $1.1B | $1.1B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | 0.00× | ||
| Q2 25 | 0.12× | 0.00× | ||
| Q1 25 | 0.12× | 0.01× | ||
| Q4 24 | 0.15× | 0.01× | ||
| Q3 24 | 0.12× | 0.02× | ||
| Q2 24 | 0.13× | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $-1.9M | ||
| Q3 25 | $14.0M | $22.0M | ||
| Q2 25 | $6.8M | $34.8M | ||
| Q1 25 | $25.7M | $-38.9M | ||
| Q4 24 | $57.9M | $13.9M | ||
| Q3 24 | $23.0M | $-15.3M | ||
| Q2 24 | $27.8M | $8.3M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $-37.2M | ||
| Q3 25 | $7.0M | $-6.4M | ||
| Q2 25 | $-4.2M | $17.0M | ||
| Q1 25 | $19.0M | $-66.4M | ||
| Q4 24 | $53.1M | $-1.3M | ||
| Q3 24 | $20.0M | $-32.9M | ||
| Q2 24 | $21.9M | $-5.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | -13.9% | ||
| Q3 25 | 3.9% | -2.1% | ||
| Q2 25 | -2.4% | 5.6% | ||
| Q1 25 | 11.3% | -23.7% | ||
| Q4 24 | 29.6% | -0.5% | ||
| Q3 24 | 11.7% | -14.5% | ||
| Q2 24 | 12.8% | -2.0% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 3.8% | 13.2% | ||
| Q3 25 | 3.9% | 9.3% | ||
| Q2 25 | 6.3% | 5.8% | ||
| Q1 25 | 4.0% | 9.8% | ||
| Q4 24 | 2.7% | 6.3% | ||
| Q3 24 | 1.8% | 7.7% | ||
| Q2 24 | 3.4% | 4.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 9.41× | ||
| Q1 25 | 3.89× | -29.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | 1.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
MTUS
Segment breakdown not available.
